Jin Hye Young, Lee Jun Ah
Department of Pediatrics, Center for Pediatric Cancer, National Cancer Center, Goyang, Korea.
Ann Pediatr Endocrinol Metab. 2020 Sep;25(3):137-144. doi: 10.6065/apem.2040060.030. Epub 2020 Sep 30.
Maximizing accumulation of bone mass during childhood and adolescence is essential to attaining optimal peak bone mass. Childhood cancer survivors (CCS) have lower bone mineral density (BMD) than the general population. Chemotherapeutic agents including steroids and radiotherapy can affect BMD. Cancer itself, hormonal insufficiency, a poor nutritional state, and a deficit of physical activities during or after treatment also influence BMD in CCS, resulting in failure to achieve appropriate peak bone mass. Low BMD in childhood and adolescence can lead to osteoporosis in adult life and complications such as bone pain, bone deformity, and fractures. Thus, BMD in CCS should be monitored with appropriate intervention. Adequate intake of calcium and vitamin D and an increase in physical activity are recommended. Timely supplements of hormones are needed in some cases. Some publications have reported that bisphosphonate therapies using pamidronate or alendronate were well tolerated in CCS and helped increase BMD.
在儿童期和青春期使骨量积累最大化对于达到最佳峰值骨量至关重要。儿童癌症幸存者(CCS)的骨矿物质密度(BMD)低于一般人群。包括类固醇和放疗在内的化疗药物会影响骨密度。癌症本身、激素不足、营养状况差以及治疗期间或之后体力活动不足也会影响CCS的骨密度,导致无法达到适当的峰值骨量。儿童期和青春期的低骨密度可导致成年后骨质疏松以及骨痛、骨畸形和骨折等并发症。因此,应对CCS的骨密度进行监测并采取适当干预措施。建议适量摄入钙和维生素D并增加体力活动。在某些情况下需要及时补充激素。一些出版物报道,使用帕米膦酸盐或阿仑膦酸盐的双膦酸盐疗法在CCS中耐受性良好,并有助于提高骨密度。